Topical amitriptyline in burning mouth syndrome: A retrospective real‐world evidence study
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Ashley Lebel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orofacial Pain, Institute of Dental Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Hauptthemen laut MEDLINE: Burning Mouth Syndrome, Amitriptyline, Analgesics, Non-Narcotic, Administration, Topical. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the effectiveness, tolerability, and safety of topical amitriptyline as a potential route of administration for the management of burning mouth syndrome.
Background
Burning mouth syndrome is a complex, idiopathic, and debilitating orofacial pain disorder that impairs quality of life, with a prevalence of up to 18% in menopausal women. Available drugs to alleviate its burning sensation have inconsistent and limited efficacy. Given its physicochemical properties, excellent tolerability, and ability to target peripheral pathways, topical amitriptyline seems a promising mechanistically specific analgesic drug for burning mouth syndrome.
Methods
In this retrospective cross‐sectional real‐world evidence study, patients with burning mouth syndrome who were prescribed topical amitriptyline for 8 weeks were identified. Eligibility criteria stemmed from ICHD‐3, ICOP, and consensus definitions. The primary outcome measure was mean daily pain intensity (on a 0–10 scale); secondary outcomes included adverse events and patient global impression of improvement. Data are given as the mean ± SD.
Results
A total of 15 patients fulfilling the eligibility criteria were included and analyzed. Mean daily pain was 6.7 ± 2.1 at baseline and 3.7 ± 2.3 after treatment, with a mean reduction of 3.1 ± 2.8 ( p = 0.002). Half of the patients experienced a decrease in pain by at least 50% ( p = 0.008). Several mild adverse events were reported, such as somnolence or dry mouth.
Conclusions
Topical amitriptyline may be a safe and potent route of administration in the treatment of burning mouth syndrome, a hypothesis to be tested in further controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orofacial Pain, Institute of Dental Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Department of Orofacial Neurobiology (LabNOF EA7543), Orofacial Pathologies, Imaging and Biotherapies URP2496, Université Paris Cité, Montrouge, France.
- Gene Regulation and Adaptive Behaviors, CNRS UMR8246, INSERM, Neuroscience Paris Seine, Sorbonne Université, Paris, France.
ORCID-Profile: Ashley Lebel, Yves Boucher
Zitieren
APA
Lebel, A., Da Silva Vieira, D., & Boucher, Y. (2024). Topical amitriptyline in burning mouth syndrome: A retrospective real‐world evidence study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14818
Vancouver
Lebel A, Da Silva Vieira D, Boucher Y. Topical amitriptyline in burning mouth syndrome: A retrospective real‐world evidence study. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14818
BibTeX
@article{Lebel2024,
author = {Lebel, Ashley and Da Silva Vieira, Dylan and Boucher, Yves},
title = {Topical amitriptyline in burning mouth syndrome: A retrospective real‐world evidence study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14818}
}
EUVIMED